Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.56 |
| ▸ | CDK1 | P06493 | 7/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4248210 | 0.99 | CDK2 (0.55) | CDK2CDK1KCNH2JAK2JAK1 | |
| Hydrochloric Acid SCHEMBL4248904 | 0.93 | CDK2 (0.54) | CDK2CDK1KCNH2JAK2JAK1 | |
| SCHEMBL13879009 | 0.90 | CDK2 (0.60) | CDK2CDK1KCNH2JAK2JAK1 | |
| SCHEMBL3936428 | 0.90 | CDK2 (0.63) | CDK2CDK1KCNH2JAK2JAK1 | |
| Hydrochloric Acid SCHEMBL4251768 | 0.89 | CDK2 (0.59) | CDK2CDK1KCNH2JAK2JAK1 | |
| Hydrochloric Acid SCHEMBL4254790 | 0.89 | CDK2 (0.62) | CDK2CDK1KCNH2JAK2JAK1 | |
| SCHEMBL13878976 | 0.89 | CDK2 (0.60) | CDK2CDK1KCNH2JAK2JAK1 | |
| SCHEMBL3945135 | 0.89 | CDK2 (0.70) | CDK2CDK1KCNH2JAK2 | |
| Hydrochloric Acid SCHEMBL4246870 | 0.89 | CDK2 (0.59) | CDK2CDK1KCNH2JAK2JAK1 | |
| SCHEMBL3936313 | 0.88 | CDK2 (0.55) | CDK2CDK1KCNH2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | DPYD, TYMS, TYMP | CDK2 174/4885CDK1 253/4885KCNH2 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.